Entrada Therapeutics (TRDA) FCF Margin (2023 - 2025)
Historic FCF Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 1743.62%.
- Entrada Therapeutics' FCF Margin fell 16163600.0% to 1743.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 210.98%, marking a year-over-year decrease of 2028700.0%. This contributed to the annual value of 21.21% for FY2024, which is 1252300.0% down from last year.
- Entrada Therapeutics' FCF Margin amounted to 1743.62% in Q3 2025, which was down 16163600.0% from 1526.36% recorded in Q2 2025.
- Entrada Therapeutics' FCF Margin's 5-year high stood at 798.62% during Q1 2023, with a 5-year trough of 1743.62% in Q3 2025.
- Moreover, its 3-year median value for FCF Margin was 86.21% (2024), whereas its average is 286.73%.
- In the last 5 years, Entrada Therapeutics' FCF Margin soared by 2424600bps in 2024 and then tumbled by -16163600bps in 2025.
- Quarter analysis of 3 years shows Entrada Therapeutics' FCF Margin stood at 11.92% in 2023, then plummeted by -623bps to 86.21% in 2024, then crashed by -1923bps to 1743.62% in 2025.
- Its FCF Margin stands at 1743.62% for Q3 2025, versus 1526.36% for Q2 2025 and 192.87% for Q1 2025.